GE HealthCare (GEHC) Q3 2026 earnings review
GE HealthCare raises its profit plan, but order growth slows
GE HealthCare, the maker of hospital scanners and imaging agents, fixed its two biggest profit problems in the third quarter. Sales from businesses owned a year ago rose 6%, well above the company's own plan, as the troubled patient-monitoring unit returned to profit and operating margin excluding one-offs climbed nearly 2 percentage points. Chief executive Peter Arduini raised the full-year outlook, though by our math the new plan has underlying sales growth slowing to about 3% in the fourth quarter.
| Sales from businesses owned a year ago | +6.2% guided 3.0–4.0% |
|---|---|
| Operating margin, excluding one-offs | 16.6% +1.8 percentage points from a year ago |
| Profit per share, excluding one-offs | $1.34 +25.1% from a year ago |
| Full-year profit per share outlook | Raised $0.10 middle of the range: $5.00 (+8.9%) |
⚖️ Verdict: 🟢 Bullish
The story got better because both the second-half margin doubt and the patient-monitoring loss reversed in the same quarter. Every division expanded its profit margin, and the company agreed to buy SOFIE Biosciences for $945 million to distribute its highest-margin imaging agents. One caution: order growth cooled to 4% from 11% last quarter, and acquisition spending has drawn down cash and paused share buybacks.
The question now is whether the patient-monitoring rebound and 6% sales pace are durable or just a one-quarter catch-up on delayed shipments. If hospital demand is truly speeding up, fourth-quarter results will beat the implied 3% pace; if Q3 was a catch-up, growth will settle back down. Fourth-quarter orders and the conclusion of the patient-monitoring review will tell.
🐂 Bull Case
Operating Margin Turned Positive Across Every Division
GE HealthCare's profit margin had shrunk from a year earlier in each of the past four quarters, which made its full-year profit plan look hard to reach. Chief executive Peter Arduini said, "We delivered strong top-line growth and margin expansion across all segments, and robust EPS growth in the third quarter." Operating margin excluding one-offs rose 1.8 percentage points to 16.6%.
- Cost of making products and delivering services: 59.7% of sales, down 1.7 percentage points from a year ago by our math
- Selling and administrative overhead: 20.0% of sales, down 0.4 percentage points by our math
- Advanced Imaging Solutions (scanners and ultrasound) profit margin: 15.3%, up 1.3 percentage points
This matters because the medical-scanner maker needed a big second-half step-up to hit its annual goal. Lower production costs, higher prices, and smaller net tariff expenses paid for component inflation. Because the third quarter did so much of the work, GE HealthCare raised the bottom of its full-year margin target to 15.5%.
What to watch: fourth-quarter operating margin excluding one-offs, which by our math needs to reach about 17.9% to hit the middle of the new full-year plan. Reaching that level would prove the pricing gains are durable.
Patient Care Swung Back to Profit as Its Boss Left
Patient Care Solutions, the division that makes hospital monitors and anesthesia machines, shrank for five straight quarters and lost $26 million in the second quarter. Management put the unit under a strategic review three months ago, including a possible sale, after blaming supply and shipping problems.
In the third quarter, sales from businesses owned a year ago jumped 8.8% to $795 million, and operating profit reached $68 million, or 8.6% of sales. At the same time, the company said division head Jeannette Bankes is "leaving for a CEO role at a publicly traded company" and named product strategy head Neal Sandy to replace her. One quarter of recovery eases the immediate profit drag, but the leadership change and open review leave the unit's future unsettled.
What to watch: fourth-quarter revenue in Patient Care Solutions and any decision on the strategic review by early 2027. A second quarter of growth would show the shipping fix is permanent rather than a one-time catch-up on delayed orders.
Diagnostic Agents Kept Growing and Added a US Network
Pharmaceutical Diagnostics, which sells contrast dyes and radioactive tracers that make medical scans clearer, is the company's most profitable business at a 29.9% operating margin. Even against its toughest comparison of the year, underlying sales rose 13.8% to $852 million, and segment profit grew 14.9% to $253 million.
To keep that engine running, the healthcare group agreed in October to buy SOFIE Biosciences for $945 million in cash, "establishing a 'final mile' footprint for PET radiopharmaceutical supply in the U.S." Radioactive tracers decay quickly, so owning local production pharmacies helps GE HealthCare deliver its new heart and cancer imaging agents to hospitals on time.
What to watch: underlying sales growth in Pharmaceutical Diagnostics in 2027, when generic rivals are expected to enter the contrast-dye market. Double-digit growth in radioactive tracers will need to offset any price pressure in older contrast dyes.
Positives this quarter didn't test
Two standing drivers from earlier quarters had either a regulatory milestone with no revenue impact yet or no new numbers in the release.
- Photonova Spectra European approval: the company's new photon-counting CT scanner gained its CE Mark on schedule in the third quarter; commercial orders in Europe will test demand in 2027.
- Multi-year hospital alliances: no new enterprise contract totals appeared in the release after last quarter's $500 million Catholic Health deal; the conference call or annual report will show how fast those deals turn into orders.
🐻 Bear Case
Order Growth Slowed and the Plan Implies a Cooler Q4
Arduini said, "With our improved performance year-to-date and momentum in the business, we are raising guidance for the year." Yet the forward-looking numbers in the release cooled down from the second quarter's peak, and the raised full-year plan points to slower growth at year-end.
- Order growth from businesses owned a year ago: 4.0%, down from 11.1% in the second quarter
- Book-to-bill (orders divided by sales): 1.03 times, down from 1.15 times last quarter
- Total backlog of unfilled orders and service contracts: $23.7 billion, down $200 million from June
- Fourth-quarter underlying sales growth implied by the full-year outlook: about 3.4% by our math, down from 6.2% in Q3
The company lifted its full-year underlying sales target by half a point at the middle of the range, to about 4.0%. Because third-quarter sales beat the old plan by 2.7 percentage points, the new target merely banks part of the third-quarter beat rather than raising the fourth-quarter trajectory.
What to watch: fourth-quarter order growth against an easy 2% comparison from a year ago. A reading below high-single digits would show that hospital equipment demand is slowing.
Acquisitions Consumed Cash and Stopped Share Buybacks
GE HealthCare spent $2.3 billion in cash on acquisitions in the first nine months of 2026, mainly for cloud-imaging firm Intelerad, and just committed another $945 million in cash for SOFIE Biosciences. That deal-making has drawn down its cash pile and halted the share buybacks management accelerated in the spring.
Cash and restricted cash fell to $2.85 billion at the end of September from $4.51 billion at the end of 2025, lifting net debt by $1.63 billion by our math while total debt stayed at $10.0 billion. After buying back $200 million of stock in the second quarter, the company spent nothing on buybacks in the third quarter.
What to watch: how the company pays for the $945 million SOFIE deal in the first half of 2027 while $1.75 billion of existing debt comes due in November 2027. Borrowing more to fund the deal would keep interest costs high.
Risks this quarter didn't answer
Seven standing risks from prior quarters could not be tested from the earnings release alone because their disclosures live in the conference call or the quarterly filing.
- Flyrcado weekly doses: not in the release; the call remarks will show whether the heart-imaging agent is accelerating toward its $500 million 2028 goal.
- Permanent finance chief: no successor to Jay Saccaro was named in the release; an appointment will show who owns the 2027 profit plan.
- China sales: regional revenue awaits the quarterly filing to see if China is still shrinking as assumed.
- Generic contrast-dye competition: awaits call commentary on 2027 pricing exposure.
- Standalone scanner margins: combining Imaging and ultrasound into one division still hides the former Imaging unit's margin.
- Tariff refund collection: the release notes $55 million of cash refunds in Q3; the filing will update the remaining receivable.
- Legal and tax disputes: the quarterly filing's footnotes will update the Iraq lawsuit and IRS tax audit.
👓 Other Themes
Tariff Relief Helped Offset Component Inflation
Import tariffs, which cut profit heavily in 2025, turned into a tailwind this quarter. GE HealthCare said higher margins were "driven by volume, price and cost productivity, and favorable year-over-year net tariff impact, partially offset by inflation." The company also collected $55 million of tariff refunds in cash during the quarter and excluded $9 million of pre-tax refunds for 2025 tariffs from its adjusted profit.
💲 Other KPIs
Free cash flow — operating cash left after capital spending — rose 64.2% from a year ago, up from $68 million in Q2 and $112 million in Q1. The figure includes a $55 million tariff refund; excluding that one-off, cash flow still grew 52.8% by our math on higher profit.
Stockpiles of parts and finished machines rose 14.1% from a year ago by our math, roughly double the 7.2% pace of sales growth, and are up from $2,483 million in June. Building inventory absorbed $430 million of operating cash over the first nine months of the year.
Contract liabilities — cash customers have paid upfront for equipment and service not yet delivered — grew 12.4% from a year ago by our math, outpacing the 7.2% rise in reported revenue. The balance rose from $2,095 million at year-end and $2,200 million in June.
🔮 Guidance
Raised. Management lifted the plan from a 3.0–4.0% range to the top end at about 4.0% after 4.2% growth in the first nine months. By our math, that leaves about 3.4% growth for the fourth quarter, down from 6.2% in Q3 against a 4.8% comparison a year ago.
Raised. The medical-technology group lifted the bottom of its margin range by 0.1 percentage points, calling for 0.2 to 0.4 points of expansion over 2025's 15.3%. With the first nine months at 14.8%, hitting the 15.6% middle of the range requires about 17.9% in Q4 by our math, up from 16.7% a year ago.
Raised. The middle of the range moved up $0.10 to $5.00, or 8.9% growth for the year, recovering most of the $0.15 cut made in the first quarter. By our math, that leaves $1.54 for the fourth quarter, or 6.9% growth from a year ago after 25.1% growth in Q3.
Raised. The company turned its approximate $1.6 billion target into a floor of at least $1.6 billion after generating $973 million in the first nine months. By our math, the floor requires at least $627 million in the fourth quarter, compared with $916 million in the fourth quarter of 2025.
Unchanged. The full-year tax rate plan stays at 20.0% to 21.0% for a third straight quarter. The rate ran at 22.0% in the third quarter and 19.9% over the first nine months, so landing inside the range requires a fourth-quarter tax rate slightly above 20%.
❓ Key Questions
How many Flyrcado doses were delivered per week in Q3?
The company gave weekly dose counts for its new heart-imaging tracer on the last three calls to back its $500 million 2028 sales goal, but the release omits the figure. The pace of doses shows whether theSOFIE pharmacy deal is needed to fix a bottleneck.
Does the Patient Care rebound change the strategic review?
Patient Care Solutions swung from a $26 million loss in Q2 to a $68 million profit in Q3, while its division president left for another company. Investors need to know whether management now plans to keep the unit or sell it into the rebound.
Why does the raised outlook imply 3.4% Q4 sales growth?
Third-quarter underlying sales grew 6.2%, yet the updated full-year plan of about 4.0% points to roughly 3.4% growth in Q4 by our math. Management should explain whether hospital installations are slowing or if the plan is simply cautious.
How will GE HealthCare fund the $945 million SOFIE deal?
Cash has fallen by $1.66 billion this year to $2.85 billion after the Intelerad purchase, and $1.75 billion of debt matures in November 2027. Investors need to know if the SOFIE purchase will require new borrowing or keep share buybacks on hold.